News

  1. Strategic Investment Increases xRNA-Based LNP Formulation Services At Caponago Injectable Facility 6/1/2022

    CordenPharma, a full-service Contract Development Manufacturing Organization (CDMO) of Active Pharmaceutical Ingredients (APIs), Excipients, Drug Products & Packaging services, has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy

  2. Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities With New Production Block At Pithampur Site 5/24/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced a new production block has come online at the company's drug product site in Pithampur, in the state of Madhya Pradesh, India

  3. BD And Mitsubishi Gas Chemical Have Signed A Letter Of Intent (LOI) To Discuss A Partnership Agreement To Explore New Ways To Advance Biologic Drug Delivery 5/19/2022

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Mitsubishi Gas Chemical Company, Inc. (MGC), a R&D-oriented chemical manufacturer based in Tokyo, Japan, today announced that they have entered into an agreement to investigate further development of OXYCAPT™ - an innovation from MGC that integrates the best of plastic and glass for plastic syringes.

  4. Piramal Pharma Solutions New API Plant In Canada Goes Online; Initial Production Runs Successfully Completed 5/19/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario, has come online and successfully completed its initial production runs

  5. Kindeva And BOL Pharma Using Low Global Warming Potential (GWP) Propellant In Development Of Inhaled Cannabinoid Products 5/11/2022

    Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis.

  6. PCI Pharma Services Announces Major Manufacturing Expansion With $100 Million Investment In New England, Providing Global Capacity To Clients 5/11/2022

    PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology, an important manufacturing process commonly used with injectable and biologic therapies, with the investment of $100 million into the construction and enhancement of world-class facilities, at its Bedford, New Hampshire campus.

  7. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA In Europe 5/5/2022

    Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA capsules (methylphenidate hydrochloride extended-release capsules) in Europe.

  8. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA® In Europe 5/5/2022

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA® capsules (methylphenidate hydrochloride extended-release capsules) in Europe

  9. Grand River Aseptic Manufacturing Invests $160M With Award From U.S. Government To Support Continued And Future Growth 4/28/2022

    Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense

  10. CDMO Grand River Aseptic Manufacturing To Invest $160 Into Manufacturing Expansion In Michigan 4/28/2022

    Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense.